CEO Interview
Gary Wilcox, Ph.D., Chairman and CEO provides background on Cocrystal and the Company's innovative and Nobel Prize winning expertise during Facebook Live interview at Nasdaq Market Site.
About Us
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses.
Learn MoreTechnology
We utilize unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.
Learn MoreDevelopment Programs
Our development programs include a wide variety of serious and/or chronic viral diseases including hepatitis C, influenza and norovirus.
Learn More| Program | Discovery | Preclinical | Phase 1 | Phase 2a | Phase 3 |
|---|---|---|---|---|---|
|
Hepatitis C
CC-31244 - University of MD (Pan-genotypic NS5B NNI) |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2a Phase in progress
|
Phase 3 Phase not started
|
|
Hepatitis C
CC-31244 - Hong Kong (Pan-genotypic NS5B NNI) |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2a Phase in progress
|
Phase 3 Phase not started
|
|
Influenza
CC-42344 (Influenza A PB2 Inhibitor) |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2a Phase not started
|
Phase 3 Phase not started
|
| Influenza Influenza A/B Inhibitor |
Discovery Phase in progress
|
Preclinical Phase not started
|
Phase 1 Phase not started
|
Phase 2a Phase not started
|
Phase 3 Phase not started
|
| Norovirus Noro Polymerase Inhibitor |
Discovery Phase in progress
|
Preclinical Phase not started
|
Phase 1 Phase not started
|
Phase 2a Phase not started
|
Phase 3 Phase not started
|
Latest News
Stock Data
Nasdaq:
COCP
Change
Volume
Market Cap